Randomized trial to evaluate tile clinical benefits of serum α- glutathione S-transferase concentration monitoring after liver transplantation

Transplantation

Volumn 64, Issue 10, 1997, Pages 1446-1452

  Hughes, Victoria F ^a   Trull, Andrew K ^a   Gimson, Alexander ^a   Friend, Peter J ^a   Jamieson, Neville ^a   Duncan, Aléna ^a   Wight, Derek G D ^a   Prevost, A Toby ^b   Alexander, Graeme J M ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; GLUTATHIONE TRANSFERASE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; LIVER CELL DAMAGE; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; MALE; PATIENT MONITORING; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030780597     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199711270-00013     Document Type: Article

References (42)

1. Sabesin SM, Williams JW. Current status of liver transplantation. Hosp Pract 1987; 22: 75.
2. Wiesner RH, Ludwig J, Krom RAF, Hay JE, Van Hoek B. Hepatic allograft rejection: new developments in terminology, diagnosis, prevention and treatment. Mayo Clin Proc 1993; 68: 69.
3. Hubscher SG. Histological findings in liver allograft rejection: new insights into the pathogenesis of hepatocellular damage in liver allografts. Histopathology 1991; 18: 377.
4. Wight DGD: Pathology of liver transplantation. In: Symmers WS, eds. Systemic pathology: liver, biliary tract and exocrine pancreas, vol. 1, 3rd ed. Edinburgh: Churchill Livingstone, 1994: 543.
5. Sankary HN, Williams JW, Foster PF. Can serum liver function tests differentiate rejection from other causes of liver dysfunction after hepatic transplantation? Transplant Proc 1988; 20 (suppl 1): 669S.
6. Henley KS, Lucey MR, Appleman HD, et al. Biochemical and histopathological correlation in liver transplant: the first 180 days. Hepatology 1992; 16: 688.
7. Foster PF, Sankary H, Williams JW. Study of eosinophilia and hepatic dysfunction as a predictor of rejection in human liver transplantation. Transplant Proc 1988; 20 (suppl 1): 676S.
8. Clements D, McMaster P, Elias E. Indocyanine green clearance in acute rejection after liver transplantation. Transplantation 1988; 46: 383.
9. Roe PG. Liver function tests in the critically ill patient. Clin Intens Care 1993; 4: 174.
10. 14C] aminopyrine breath test. Transplant Proc 1993; 25: 2640.
11. Gozzo ML, Avolio A, Forni F, et al. Enzymatic determinations in acute rejection after liver transplantation: preliminary report on necrosis index. Clin Chim Acta 1993; 214: 175.
12. Wu TW, Levy GA, Yui S, et al. Delta and conjugated bilirubin as complementary markers of early rejection in liver transplant recipients. Clin Chem 1990; 36: 9.
13. Hausen A, Aichberger C, Königsrainer A, Weiss G, Margreiter R, Wachter H. Biliary and urinary neopterin concentrations in monitoring liver-allograft recipients. Clin Chem 1993; 39: 45.
14. Trull AK, Facey SP, Rees GW, et al. Serum α-glutathione S-transferase: a sensitive marker of hepatocellular damage associated with acute liver allograft rejection. Transplantation 1994; 58: 1345.
15. Rees GW, Trull AK, Doyle S. Evaluation of an enzyme-immunometric assay for serum α-glutathione S-transferase. Ann Clin Biochem 1995; 32: 575.
16. Hayes PC, Hussey AJ, Keating J, et al. Glutathione S-transferase levels in autoimmune chronic hepatitis: a more sensitive index of hepatocellular damage than aspartate transaminase. CHn Chim Acta 1988; 172: 211.
17. Beckett GJ, Foster GR, Hussey AJ, et al. Plasma glutathione S-transferase and F protein are more sensitive than alanine aminotransferase as markers of paracetamol (acetaminophen)-induced liver damage. Clin Chem 1989; 35: 2186.
18. 1 in plasma after birth asphyxia: an early indication of hepatocellular damage. Clin Chem 1989; 35: 995.
19. Vaubourdolle M, Chazouillères O, Briaud I, et al. Plasma α-glutathione S-transferase assessed as a marker of liver damage in patients with chronic hepatitis C. Clin Chem 1995; 41: 1716.
20. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994; 344: 423.
21. Jonas S, Kling N, Bechstein WO, et al. Rejection episodes after liver transplantation during primary immunosuppression with FK506 or a cyclosporine-based regimen: a controlled, prospective, randomized trial. Clin Transplant 1995; 9: 406.
22. The U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331: 1110.
23. Busuttil RW, Shaked A, Millis JM, et al. One thousand liver transplants: the lessons learnt. Ann Surg 1994; 219: 490.
24. Mora NP, Klintmam GB, Cofer JB, et al. Results after retransplantation (RETx): a comparative study between "elective" vs "nonelective" RETx. Transplant Proc 1990; 22: 1509.
25. D'Alessandro Am, Ploeg RJ, Knechtle SJ, et al. Re-transplantation of the liver: a seven-year experience. Transplantation 1993; 55: 1083.
26. Keefe EB, Esquivel CO. Liver transplantation. Curr Opin Gastroenterol 1996; 12: 290.
27. Dousset B, Hubscher SG, Padbury RTA, et al. Acute liver allograft rejection: is treatment always necessary? Transplantation 1993; 55: 529.
28. Hoofnagle JH, Lombardero M, Zetterman RK, et al. Donor age and outcome of liver transplantation. Hepatology 1996; 24: 89.
29. Doyle HR, Morelli F, McMichael J, et al. Hepatic re-transplantation: an analysis of risk factors associated with outcome. Transplantation 1996; 61: 1499.
30. Detre KM, Belle SH, Beringer KC, Bost JE, Daily OP. Overall national results of liver transplantation between 1987 and 1991. In: Busuttil RW, Klintmalm GB, eds. Transplantation of the liver, 1st ed. Philadelphia: W.B. Saunders, 1996: 824.
31. Bromley PN, Hilmi I, Tan KC, Williams R, Potter D. Orthotopic liver transplantation in patients over 60 years old. Transplantation 1994; 58: 800.
32. Spanier TB, Klein RD, Nasraway SA, et al. Multiple organ failure after liver transplantation. Crit Care Med 1995; 23: 466.
33. Lake JR, German KJ, Esquivel CO, et al. The impact of immunosuppressive regimes on the cost of liver transplantation: results from the U.S. FK506 multicenter trial. Transplantation 1995; 60: 1089.
34. Snover DC, Freese DK, Sharp HL, Bloomer JR, Najarian JS, Ascher NL. Liver allograft rejection: an analysis of the use of biopsy in determining outcome of rejection. Am J Surg Pathol 1987; 11: 1.
35. McDonald JA, Painter DM, Bell R, Gallagher ND, Sheil AGR, McCaughan GW. Human liver allograft rejection: severity, prognosis and response to treatment. Transplant Proc 1989; 21: 3792.
36. Demetris AJ, Seaberg EC, Batts KP, et al. Reliability and predictive value of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database nomenclature and grading system for cellular rejection of liver allografts. Hepatology 1995; 21: 408.
37. Sherman M, Bass NM, Campbell JAH, Kirsch RE. Radioimmunoassay of human ligandin. Hepatology 1983; 3: 162.
38. Wade JJ, Rolando N, Hayllar K, Philpott-Howard J, Casewell MW, Williams R. Bacterial and fungal infections after liver transplantation: an analysis of 284 patients. Hepatology 1995; 21: 1328.
39. Kusne S, Dummer JS, Singh N, et al. Infections after liver transplantation. Medicine 1988; 67: 132.
40. Paya CV, Hermans PE, Washington JA, et al. Incidence, distribution, and outcome of episodes of infection in 100 orthotopic liver transplantations. Mayo Clin Proc 1989; 64: 555.
41. Abraham SC, Furth EE. Receiver operating characteristic analysis of serum chemical parameters as tests of liver transplant rejection and correlation with histology. Transplantation 1995; 59: 740.
42. Colina F, Mollejo M, Moreno E, et al. Effectiveness of histopathological diagnoses in dysfunction of hepatic transplantation. Arch Pathol Lab Med 1991; 115: 998.